Skin cancer risk after organ transplantation;Risque de carcinomes cutanés chez les greffés d'organe

Pathologie Biologie

Volumn 52, Issue 3, 2004, Pages 160-163

  Euvrard, S ^a   Butnaru, A C ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Basal cell carcinoma; Carcinome basocellulaire; Carcinome spinocellulaire; Greffe d'organe; Immunosuppression; Organ transplantation; Squamous cell carcinoma

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; FLUOROURACIL; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

CANCER LOCALIZATION; CANCER PATIENT; CANCER RISK; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFECT; EDITORIAL; GENETIC ANALYSIS; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; RISK ASSESSMENT; RISK FACTOR; SKIN CANCER; WART VIRUS;

EID: 1842559662     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2003.05.004     Document Type: Short Survey

References (30)

1. Euvrard S., Kanitakis J., Claudy A. Skin cancers in organ transplant recipients. New Engl. J. Med. 348:2003;1681-1691.
2. Webb M.C., Compton F., Andrews P.A., Koffman C.G. Skin tumours posttransplantation. A retrospective analysis of 28 years' experience at a single centre. Transplant Proc. 29:1997;828-830.
3. Bouwes-Bavinck J.N., Hardie D., Green A., Cutmore S., MacNaught A., O'Sullivan B., et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. Transplantation. 61:1996;715-721.
4. Euvrard S., Kanitakis J., Pouteil-Noble C., Dureau G., Touraine J.L., Faure M., et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J. Am. Acad. Dermatol. 33:1995;222-229.
5. Hartevelt M.M., Bouwes Bavinck J.N., Koote A.M.M., Vermeer B.J., Vandenbroucke J.P. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation. 49:1990;506-509.
6. Lindelöf B., Sigurgeirsson B., Gäbel H., Stern R.S. Incidence of skin cancer in 5356 patients following organ transplantation. Br. J. Dermatol. 143:2000;513-519.
7. Jensen P., Hansen S., Moller B., Leivestad T., Pfeffer P., Geiran O., et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J. Am. Acad. Dermatol. 40:1999;177-186.
8. Euvrard S., Kanitakis J., Pouteil-Noble C., Disant F., Dureau G., Finaz de Villaine J., et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc. 27:1995;1767-1768.
9. Martinez J.C., Otley C.C., Stasko T., Euvrard S., Brown C., Schanbacher C.F., et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch. Dermatol. 139:2003;301-306.
10. Ducloux D., Carron P.L., Rebibou J.M., Aubin F., Fournier V., Bresson-Vautrin C., et al. CD4 lymphopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation. 65:1998;1270-1272.
11. Hiesse C., Rieu P., Kriaa F., Larue J.R., Goupy C., Neyrat N., et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc. 29:1997;831-833.
12. Dantal J., Hourmant M., Cantarovich D., Giral M., Blancho G., Dréno B., et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 351:1998;623-628.
13. Chocair P.R., Duley J.A., Simmonds H.A., Cameron J.S. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation. 53:1992;1051-1055.
14. Hojo M., Morimoto T., Maluccio M., Asanos T., Morimoto K., Lagman M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 397:1999;530-534.
15. Harwood C.A., Surentheran T., McGregor J., Spink P.J., Leigh I., Breuer J., et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J. Med. Virol. 61:2000;289-297.
16. Berkhout R., Bouwes-Bavinck J., Ter Schegget J. Persistence of Human Papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients. J. Clin. Microbiol. 38:2000;2087-2096.
17. Boxman I.L.A., Berkhout R.J.M., Mulder L.H.C., Wolkers M.C., Bouwes Bavinck J.N., Vermeer B.J., et al. Detection of Human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J. Invest. Dermatol. 108:1997;712-715.
18. Ramsay H.M., Fryer A.A., Hawley C.M., Smith A.G., Nicol D.L., Harden P.H. Non melanoma skin cancer risk in the Queensland renal transplant population. Br. J. Dermatol. 147:2002;950-956.
19. De Hertog S.A., Wensveen C.A., Bastiaens M.T., Kielich C.J., Berkhout M.J., Westendorp R.G., et al. Relation between smoking and skin cancer. J. Clin. Oncol. 19:2001;231-238.
20. Ramsay H.M., Harden P.N., Reece S., Smith A.G., Jones P.W., Strange R.C., et al. Polymorphism in glutathione S-transferases are associated with altered risk of nonmelanoma skin cancer in renal transplant recipients: a preliminary analysis. J. Invest. Dermatol. 117:2001;251-255.
21. Cairey-Remonnay S., Humbey O., Mougin C., Algros M.P., Mauny F., Kanitakis J., et al. TP53 polymorphism of exon 4 at codon 72 in cutaneous squamous cell carcinoma and benign epithelial lesions of renal transplant recipients and immunocompetent individuals: lack of correlation with HPV status. J. Invest. Dermatol. 118:2002;1026-1031.
22. Marshall S.E., Bordea C., Haldar N., Mullighan C.G., Wojnarowska F.R., Morris P.J., et al. Glutathione S-transferase polymorphisms and skin cancer after renal transplantation. Kidney Int. 58:2000;2186-2193.
23. Alamartine E., Berthoux P., Mariat C., Cambazard F., Berthoux F. Interleukin-10 Promoter Polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J. Invest. Dermatol. 120:2003;99-103.
24. Bouwes-Bavinck J.N., Claas F., Hardie D., Green A., Vermeer B.J., Hardie I.R. Relation between HLA antigens and skin cancer in renal transplant recipients in Queensland, Australia. J. Invest. Dermatol. 108:1997;708-711.
25. Stockfleth E., Ulrich C., Meyer T., Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res. 160:2002;251-258.
26. Luan F.L., Hojo M., Maluccio M., Yamaji K., Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation. 73:2002;1565-1572.
27. Guba M., Von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8:2002;128-135.
28. Luan F.L., Ding R., Sharma V.K., Chon W.J., Lagman M., Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney international. 63:2003;917-926.
29. Yarosh D.B., Boumakis S., Brown A.B., Canning M.T., Galvin J.W., Both D.M., et al. Measurement of UVB-induced DNA damage and its consequences in models of immunosuppression. Methods. 28:2002;55-62.
30. Mathew T., Kreis H., Doyen K. Malignancy in renal transplant recipients receiving sirolimus (Rapamune*) maintenance therapy: 2-year follow-up from five multicenter studies (abst). Transplantation. 74:(S):2002;131.